Leading the Way in Life Science Technologies

GEN Exclusives

More »

Sidebars

More »
Mar 15, 2009 (Vol. 29, No. 6)

microRNA Expression Profiling of Carcinomas of Unknown Origin

  • Researchers at Exiqon published an application note describing the use of the company’s miRCURY LNA™ microRNA arrays and Tecan’s HS Pro™ hybridization station for microRNA profiling of carcinomas of unknown primary (CUP) origin. The goal of the study was to develop a classifier tool based on microRNA profiles for CUP diagnosis and the classifier itself was subsequently used to identify the tumor type of a patient suffering from CUP by analyzing a biopsy from a lymph node metastasis.

    Eighteen tissues, which represent the most common tissues of origin of CUP, were included in the analysis. The microRNA expression levels of these samples were analyzed and a unique microRNA profile for each of the 18 tissues was generated. Thus, CUP samples can now be compared to these expression profiles in order to locate their origin, report the scientists, who add that detailed analysis of these results revealed that a cancer classifier based on seven microRNAs is sufficient.

    A biopsy from a lymph node metastasis from a patient suffering from CUP was profiled on the miRCURY LNA microRNA array. The microRNA expression level of the metastasis was compared to the average expression level across the 18 tissues.

    Based on a simple cluster analysis, the lymph node metastasis microRNA profile was shown to belong to the colorectal microRNA cluster and was thus identified as colorectal cancer. Indeed, a primary colon tumor was found in this patient.

    In this case, based on the microRNA profile alone, one would be able to direct the treatment against a colon cancer without having to perform a full-body PET scan searching for the primary tumor, concluded the scientists.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »